T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy

Table 1 Clinicopathologic characteristics of the patients

Characteristic	Number	%
Total patients	196
Median age (range)	57 (26 to 76)
<65	147	75.0
≥65	49	25.0
Sex
Male	112	57.1
Female	84	42.9
Tumor location
Right	52	26.5
Transverse	8	4.1
Descending	17	8.7
Sigmoid and rectosigmoid	119	60.7
Histologic appearance
Well differentiated	6	3.1
Moderately differentiated	174	88.8
Poorly differentiated	10	5.1
Signet ring cell	1	0.5
Mucinous cell	5	2.5
Lymphovascular invasion (+)	106	54.1
Neural invasion (+)	89	45.4
T stage
T1	1	0.5
T2	5	2.5
T3	174	88.8
T4	16	8.2
N stage
N0	38	19.4
N1	86	43.9
N2	72	36.7
WBC
<4,000 × 10⁶/L	3	1.5
4,000 ~ 10,000 × 10⁶/L	169	86.2
>10,000 × 10⁶/L	24	12.3
Hemoglobin (Hgb)
Female <12 g/dL (anemia)	50	25.5
Female ≥12 g/dL (normal)	34	17.3
Male <14 g/dL (anemia)	66	33.7
Male ≥14 g/dL (normal)	46	23.5
Platelet (PLT)
<140 × 10⁹/L (thrombocytopenia)	4	2.0
140 ~ 440 × 10⁹/L	185	94.4
>440 × 10⁹/L	7	3.6
Albumin
<3.8 g/dL	40	20.4
3.8 ~ 5.3 g/dL	156	79.6
Lactate dehydrogenase (LDH)
129 ~ 240 U/L	41	20.9
>240 U/L	155	79.1
Total bilirubin
0.2 ~ 1.0 mg/dL	189	96.4
>1.0 mg/dL	7	3.6
Aspartate aminotransferase (AST)
10 ~ 33 U/L	174	88.8
>33 U/L	22	11.2
Alanine aminotransferase (ALT)
4 ~ 50 U/L	183	93.4
>50 U/L	13	6.6
Protein
<6.7 g/dL	29	14.8
6.7 ~ 8.3 g/dL	165	84.2
>8.3 g/dL	2	1.0
Prognostic model (T4, Hgb)
Low-risk group	43	21.9
Intermediate-risk group	139	70.9
High-risk group	14	7.2
Preoperative CEA
≤5 ng/mL	114	58.2
>5 ng/mL	82	41.8
Postoperative CEA
≤5 ng/mL	160	81.6
>5 ng/mL	36	18.4
Side effect
Neutropenia	154	78.6
Gastrointestinal symptoms	36	18.4
Peripheral neuropathy	40	20.4

ISSN: 1477-7819